Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 3/2015

01-03-2015 | Review Article

Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications

Authors: Geetha Ramachandran, Soumya Swaminathan

Published in: Drug Safety | Issue 3/2015

Login to get access

Abstract

Tuberculosis (TB) remains a major public health problem, representing the second leading cause of death from infectious diseases globally, despite being nearly 100 % curable. Multidrug-resistant (MDR)-TB, a form of TB resistant to isoniazid and rifampicin (rifampin), two of the key first-line TB drugs, is becoming increasingly common. MDR-TB is treated with a combination of drugs that are less effective but more toxic than isoniazid and rifampicin. These drugs include fluoroquinolones, aminoglycosides, ethionamide, cycloserine, aminosalicyclic acid, linezolid and clofazimine among others. Minor adverse effects are quite common and they can be easily managed with symptomatic treatment. However, some adverse effects can be life-threatening, e.g. nephrotoxicity due to aminoglycosides, cardiotoxicity due to fluoroquinolones, gastrointestinal toxicity due to ethionamide or para-aminosalicylic acid, central nervous system toxicity due to cycloserine, etc. Baseline evaluation may help to identify patients who are at increased risk for adverse effects. Regular clinical and laboratory evaluation during treatment is very important to prevent adverse effects from becoming serious. Timely and intensive monitoring for, and management of adverse effects caused by, second-line drugs are essential components of drug-resistant TB control programmes; poor management of adverse effects increases the risk of non-adherence or irregular adherence to treatment, and may result in death or permanent morbidity. Treating physicians should have a thorough knowledge of the adverse effects associated with the use of second-line anti-TB drugs, and routinely monitor the occurrence of adverse drug reactions. In this review, we have compiled safety and tolerability information regarding second-line anti-TB drugs in both adults and children.
Literature
1.
World Health Organisation. Global tuberculosis report, 2010. Geneva: WHO; 2010.
2.
3.
Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210 (Rev 1). Geneva: WHO; 1997.
4.
Fox W, Mitchison DA. Short course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1975;111:845–8.PubMed
5.
Hooper DC, Strahilevitz J. Quinolones. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 487–510.
6.
Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr. 2006;18(1):64–70.PubMed
7.
Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother. 1986;29(1):163–4.PubMedCentralPubMed
8.
Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992;36(4):860–6.PubMedCentralPubMed
9.
10.
Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988;32(9):1336–40.PubMedCentralPubMed
11.
Moxifloxacin. Tuberculosis (Edinb). 2008;88 (2):127–131.
12.
Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use–safety report. Pediatr Infect Dis J. 1997;16(1):127–9 (discussion 60–2).PubMed
13.
Yew WW, Chau CH, Wen KH. Pseudomembranous colitis in a patient treated with ofloxacin for tuberculosis. Tuber Lung Dis. 1996;77(5):484.PubMed
14.
Pépin J, Saheb N, Coulombe M-A, Alary M-E, Corriveau M-P, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60.PubMed
15.
Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449–56.PubMed
16.
Tome AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf. 2011;34(6):465–88.PubMed
17.
Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother. 2001;35(10):1194–8.PubMed
18.
Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353–69.PubMed
19.
Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010;24(8):655–67.PubMed
20.
Walton GD, Hon JK, Mulpur TG. Ofloxacin-induced seizure. Ann Pharmacother. 1997;31(12):1475–7.PubMed
21.
Christie MJ, Wong K, Ting RH, Tam PY, Sikaneta TG. Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure. Ann Pharmacother. 2005;39(5):953–5.PubMed
22.
Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009;65(10):959–62.PubMed
23.
Jo M, Tachi N, Shinoda M. Convulsions from excessive dosage of nalidixic acid: a case report. Brain Dev. 1979;1(4):327–9.PubMed
24.
Islam MA, Sreedharan T. Convulsions, hyperglycemia, and glycosuria from overdose of nalidixic acid. JAMA. 1965;21(192):1100–1.
25.
26.
Seddon J, Hesseling A, Finlayson L, Schaaf HS. Toxicity and tolerability of multidrug-resistant tuberculosis preventive treatment in children [abstract no. PC-646-17]. In: 43rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union): Kuala Lumpur; 2012.
27.
Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007;29(4):374–9.PubMed
28.
Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant “clinical” event? South Med J. 2006;99(1):52–6.PubMed
29.
Kang J, Wang L, Chen X-L, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122–6.PubMed
30.
Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol. 2006;11(1):52–6.PubMed
31.
Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73(4):292–303.PubMed
32.
Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004;44(5):464–73.PubMed
33.
Frothingham R. Rates of Torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21(12):1468–72.PubMed
34.
Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55(11):1457–65.PubMed
35.
Demolis J-L, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000;68(6):658–66.PubMed
36.
Osborn LA, Skipper B, Arellano I, MacKerrow SD, Crawford MH. Results of resting and ambulatory electrocardiograms in patients with hypothyroidism and after return to euthyroid status. Heart Dis. 1999;1(1):8–11.PubMed
37.
Bakiner O, Ertorer ME, Haydardedeoglu FE, Bozkirli E, Tutuncu NB, Demirag NG. Subclinical hypothyroidism is characterized by increased QT interval dispersion among women. Med Princ Pract. 2008;17(5):390–4.PubMed
38.
Unal O, Erturk E, Ozkan H, Kiyici S, Guclu M, Ersoy C, et al. Effect of levothyroxine treatment on QT dispersion in patients with subclinical hypothyroidism. Endocr Pract. 2007;13(7):711–5.PubMed
39.
Kweon KH, Park BH, Cho CG. The effects of l-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci. 2007;22(1):114–6.PubMedCentralPubMed
40.
Murphy ME, Singh KP, Laurenzi M, Brown M, Gillespie SH. Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation. Int J Tuberc Lung Dis. 2012;16(2):144–9 (i–iii).PubMed
41.
Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone-induced arthropathy in animals versus children. Clin Infect Dis. 1997;25(5):1196–204.PubMed
42.
Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J. 2003;22(12):1128–32.PubMed
43.
Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin N Am. 2005;19(3):617–28.
44.
Schaad UB. Use of quinolones in pediatrics. Eur J Clin Microbiol Infect Dis. 1991;10(4):355–60.PubMed
45.
Jafri HS, McCracken GH Jr. Fluoroquinolones in paediatrics. Drugs. 1999;58(Suppl 2):43–8.PubMed
46.
Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. Ann Pharmacother. 2000;34(3):347–59 (quiz 413–4).PubMed
47.
Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96(9):874–80.PubMedCentralPubMed
48.
Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, et al. Comparative safety profile of levofloxacin in 2,523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26(10):879–91.PubMed
49.
Li F, Nandy P, Chien S, Noel GJ, Tornoe CW. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother. 2010;54(1):375–9.PubMedCentralPubMed
50.
Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21(6):525–9.PubMed
51.
52.
Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculo-skeletal toxicity five years after therapy with levofloxacin. Paediatr. 2014;134(1):e146–53.
53.
Tumbanatham A, Vinodkumar S. Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis. J Assoc Physicians India. 2000;48(6):647–8.PubMed
54.
Arora VK, Tumbanatham A. Severe arthropathy with ofloxacin in two cases of MDR tuberculosis. Int J Tuberc Lung Dis. 1998;2(11):941–3.PubMed
55.
Wong HY, Chau CH, Yew WW. Moxifloxacin-induced arthropathy. Int J Tuberc Lung Dis. 2007;11(1):117.PubMed
56.
Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy. 2004;24(12):1807–12.PubMed
57.
Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol. 2001;16(9):1028–32.PubMed
58.
Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res. 1992;12(4):173–8.PubMed
59.
Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC, Luh KT. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis. 2009;48(11):1526–33.PubMed
60.
Roberts CH, Smith C, Breen R, Gadhok R, Murphy M, Aryee A, et al. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Int J Tuberc Lung Dis. 2011;15(9):1275–6.PubMed
61.
62.
Gilbert DN, Leggett JE. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 359–84.
63.
64.
Kawaguchi H. Discovery, chemistry, and activity of amikacin. J Infect Dis. 1976;134:S242–8.PubMed
65.
Capreomycin. Tuberculosis (Edinb). 2008;88(2):89–91.
66.
Evaluation of a new antituberculous agent. Capreomycin sulfate (capastat sulfate). JAMA. 1973;223(2):179–80.
67.
Bycroft BW, Cameron D, Croft LR, Hassanali-Walji A, Johnson AW, Webb T. Total structure of capreomycin IB, a tuberculostatic peptide antibiotic. Nature. 1971;231(5301):301–2.PubMed
68.
Dauby N, Payen MC. Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis. 2010;14(5):657–8.PubMed
69.
Lemos AC, Matos ED. Multidrug–resistant tuberculosis. Braz J Infect Dis. 2013;17(2):239–46.PubMed
70.
71.
Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549–55.PubMedCentralPubMed
72.
Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11(12):1314–20.PubMed
73.
de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6(7):622–7.PubMed
74.
Shin S, Furin J, Alcantara F, Hyson A, Joseph K, Sanchez E, et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest. 2004;125(3):974–80.PubMed
75.
Keating MJ, Sethi MR, Bodey GP, Samaan NA. Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy. Cancer. 1977;39(4):1410–4.PubMed
76.
77.
Hesling CM. Treatment with capreomycin, with special reference to toxic effects. Tubercle. 1969;50(Suppl):39–41.PubMed
78.
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798–807.PubMed
79.
Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryng. 2011;2011:1–19.
80.
Bardien S, Human H, Harris T, Hefke G, Veikondis R, Schaaf HS, et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet. 2009;10:2.PubMedCentralPubMed
81.
Human H, Hagen CM, de Jong G, Harris T, Lombard D, Christiansen M, et al. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides. Biochem Biophys Res Commun. 2010;393(4):751–6.PubMed
82.
Xing G, Chen Z, Cao X. Mitochondrial rRNA and tRNA and hearing function. Cell Res. 2007;17(3):227–39.PubMed
83.
O’Donnell EP, Scarsi KK, Scheetz MH, Postelnick MJ, Cullina J, Jain M. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. Int J Antimicrob Agents. 2010;36(1):94–5.PubMed
84.
Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother. 1987;31(9):1383–7.PubMedCentralPubMed
85.
Tran Ba Huy P, Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988;105(5–6):511–5.PubMed
86.
Pettorossi VE, Ferraresi A, Errico P, Draicchio F, Dionisotti S. The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Eur Arch Otorhinolaryngol. 1990;247(5):277–82.PubMed
87.
Takumida M, Nishida I, Nikaido M, Hirakawa K, Harada Y, Bagger-Sjoback D. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. J Otorhinolaryngol Relat Spec. 1990;52(6):341–9.
88.
Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538–44.PubMed
89.
Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40(5):1277–86.PubMed
90.
Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012;102(6):363–6.PubMed
91.
Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect. 2013;66(4):320–9.PubMed
92.
Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117(6):2022–9.PubMed
93.
Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis. 2011;11:28.PubMedCentralPubMed
94.
Rist N, Grumbach F, Libermann D. Experiments on the antituberculous activity of alpha-ethylthioisonicotinamide. Am Rev Tuberc. 1959;79(1):1–5.PubMed
95.
Ethionamide. Tuberculosis. 2008;88(2):106–8.
96.
Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR Jr, et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007;204(1):73–8.PubMedCentralPubMed
97.
Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263(5144):227–30.PubMed
98.
Kass I. Chemotherapy regimens used in retreatment of pulmonary tuberculosis. Observations on the efficacy of combinations of kanamycin, ethionamide and either cycloserine or pyrazinamide. Tubercle. 1965;46:151–65.PubMed
99.
Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, Hurtado RM, Amanullah F, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012;186(10):953–64.PubMed
100.
Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB, et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2009;13(9):1161–6.PubMed
101.
A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association. Tubercle. 1968;49(2):125–35.
102.
Comparison of the clinical usefulness of ethionamide and prothionamide in initial treatment of tuberculosis: tenth series of controlled trials. Tubercle. 1968;49(3):281–90.
103.
Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-induced goitrous hypothyroidism. Ann Intern Med. 1984;100(6):837–9.PubMed
104.
Soumakis SA, Berg D, Harris HW. Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis. Clin Infect Dis. 1998;27(4):910–1.PubMed
105.
McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N Engl J Med. 2005;352(26):2757–9.PubMed
106.
Thee S, Zollner EW, Willemse M, Hesseling AC, Magdorf K, Schaaf HS. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis. 2011;15(9):1191–3 (i).PubMed
107.
Satti H, Mafukidze A, Jooste PL, McLaughlin MM, Farmer PE, Seung KJ. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int J Tuberc Lung Dis. 2012;16(4):468–72.PubMed
108.
Gupta J, Breen RAM, Milburn HJ. Drug-induced hypothyroidism in patients receiving treatment for multidrug-resistant tuberculosis in the UK [correspondence]. Int J Tuberc Lung Dis. 2012;16(9):1278.PubMed
109.
Modongo C, Zetola NM. Prevalence of hypothyroidism among MDR-TB patients in Botswana [correspondence]. Int J Tuberc Lung Dis. 2012;16(11):1561–2.PubMedCentralPubMed
110.
Dutta BS, Hassan G, Waseem Q, Saheer S, Singh A. Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis. 2012;16(1):141.PubMed
111.
Hollinrake K. Acute hepatic necrosis associated with ethionamide. Br J Dis Chest. 1968;62(3):151–4.PubMed
112.
Swash M, Roberts AH, Murnaghan DJ. Reversible pellagra-like encephalopathy with ethionamide and cycloserine. Tubercle. 1972;53(2):132–6.PubMed
113.
Narang RK. Acute psychotic reaction probably caused by ethionamide. Tubercle. 1972;53(2):137–8.PubMed
114.
Lansdown FS, Beran M, Litwak T. Psychotoxic reaction during ethionamide therapy. Am Rev Respir Dis. 1967;95(6):1053–5.PubMed
115.
116.
Dixit R, George J, Sharma AK, Chhabra N, Jangir SK, Mishra V. Ethionamide-induced gynecomastia. J Pharmacol Pharmacother. 2012;3(2):196–9.PubMedCentralPubMed
117.
Ticholov K, Dobrev P. Severe hypoglycemic manifestations in tuberculous diabetes treated with ethionamide. Tuberkulosearzt. 1963;17:439–46.PubMed
118.
Prothionamide. Tuberculosis. 2008;88(2):139–40.
119.
Cycloserine. Tuberculosis (Edinb). 2008;88(2):100–1.
120.
Chen JM, Uplekar S, Gordon SV, Cole ST. A point mutation in cycA partially contributes to the d-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains. PLoS One. 2012;7(8):e43467.PubMedCentralPubMed
121.
Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Structure of the Mycobacterium tuberculosis d-alanine: d-alanine ligase, a target of the antituberculosis drug d-cycloserine. Antimicrob Agents Chemother. 2011;55(1):291–301.PubMedCentralPubMed
122.
Halouska S, Chacon O, Fenton RJ, Zinniel DK, Barletta RG, Powers R. Use of NMR metabolomics to analyze the targets of d-cycloserine in mycobacteria: role of d-alanine racemase. J Proteome Res. 2007;6(12):4608–14.PubMedCentralPubMed
123.
Zitkova L, Tousek J. Pharmacokinetics of cycloserine and terizidone. A comparative study. Chemotherapy. 1974;20(1):18–28.PubMed
124.
Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–83.PubMed
125.
Kwon HM, Kim HK, Cho J, Hong YH, Nam H. Cycloserine-induced encephalopathy: evidence on brain MRI. Eur J Neurol. 2008;15(7):e60–1.PubMed
126.
Holmes CX, Martin GE, Fetterhoff KI. The role of the cycloserine (seromycin) blood level in the treatment of pulmonary tuberculosis and the prevention and control of cycloserine (seromycin) toxicity. Dis Chest. 1959;36:591–3.PubMed
127.
Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90(5):279–92.PubMed
128.
Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8(6):749–59.PubMed
129.
Shim JH, Kim TY, Kim HO, Kim CW. Cycloserine-induced lichenoid drug eruption. Dermatology. 1995;191(2):142–4.PubMed
130.
Akula SK, Aruna AS, Johnson JE, Anderson DS. Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 1997;1(2):187–90.PubMed
131.
132.
133.
Steiner M. Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children. Med Clin N Am. 1967;51(5):1153–67.PubMed
134.
Battaglia B, Kaufman I, Lyons HA, Marsh W. Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children. Am Rev Respir Dis. 1961;83:751–2.PubMed
135.
Schloss J, Ismail Z. Cycloserine and isoniazid in childhood tuberculous infections. Antibiotic Med Clin Ther. 1960;7:244–8.
136.
Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet. 1946;1(6384):15.PubMed
137.
Para-aminosalicylic acid. Tuberculosis. 2008;88(2):137–8.
138.
Ratledge C. Iron, mycobacteria and tuberculosis. Tuberculosis (Edinb). 2004;84(1–2):110–30.PubMed
139.
Durham NN, Hubbard JS. Mechanism of competitive inhibition of p-aminobenzoic acid oxidation by p-aminosalicylic acid. J Bacteriol. 1960;80:225–31.PubMedCentralPubMed
140.
Durham NN, Hubbard JS. Antagonism of the oxidative dissimilation of p-aminobenzoic acid by p-aminosalicylic acid. Nature. 1959;184(Suppl 18):1398.PubMed
141.
Lehmann J. The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review. Dis Chest. 1949;16(6):684–703.PubMed
142.
Woolley PB. The use of antrenyl in gastro-intestinal irritation due to PAS compounds. Br J Tuberc Dis Chest. 1957;51(4):382–4.PubMed
143.
Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med. 1999;159(3):932–4.PubMed
144.
145.
Balint JA, Fraser R, Hanno MG. Radio-iodine measurements of thyroid function during and after P.A.S. treatment of tuberculosis. Br Med J. 1954;1(4873):1234–7.PubMedCentralPubMed
146.
147.
148.
Macgregor AG, Somner AR. The anti-thyroid action of para-aminosalicylic acid. Lancet. 1954;267(6845):931–6.PubMed
149.
150.
Edwards DA, Rowlands EN, Trotter WR. The mechanism of the goitrogenic action of p-aminosalicylic acid. Lancet. 1954;267(6847):1051–2.PubMed
151.
Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, et al. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One. 2012;7(5):e37114.PubMedCentralPubMed
152.
Matsaniotis N, Jacobs J, Smith MH. Hypersensitivity reactions associated with sodium para-aminosalicylate therapy; four case reports and review of the literature. Pediatrics. 1958;21(5):781–92.PubMed
153.
154.
Ge QP, Wang QF, Duan HF, Wang J, Chu NH. Clinical analysis of prothionamide and para amino salicylic acid induced hepatotoxicity. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36(10):737–40.PubMed
155.
Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358(9297):1975–82.PubMed
156.
Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997;41(10):2132–6.PubMedCentralPubMed
157.
Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41(10):2127–31.PubMedCentralPubMed
158.
De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111–7.PubMed
159.
Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl 1):S59–74.PubMed
160.
Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. J Antimicrob Chemother. 2011;66(Suppl 4):iv23–41.PubMed
161.
Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010;32(1):66–88.PubMed
162.
Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge-Padbury B, Naberhuis-Stehouwer S, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S193–200.PubMed
163.
Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–6.PubMedCentralPubMed
164.
Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508–18.PubMed
165.
Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J. 2003;22(9 Suppl):S186–92.PubMed
166.
Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4(8):528–31.PubMed
167.
Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother. 2004;54(4):832–5.PubMed
168.
Nambiar S, Rellosa N, Wassel RT, Borders-Hemphill V, Bradley JS. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics. 2011;127(6):e1528–32.PubMed
169.
Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, Martin A, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S172–7.PubMed
170.
Su E, Crowley K, Carcillo JA, Michaels MG. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 2011;30(9):804–6.PubMedCentralPubMed
171.
Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis. 2012;16(12):1588–93.PubMed
172.
French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl 2):ii 45–53.
173.
Reddy VM, O’Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother. 1999;43(5):615–23.PubMed
174.
Clofazimine. Tuberculosis. 2008;88(2):96–9.
175.
176.
Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011;286(12):10276–87.PubMedCentralPubMed
177.
Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci. 2012;109(30):12147–52.PubMedCentralPubMed
178.
Ramu G, Iyer GG. Side effects of clofazimine therapy. Lepr India. 1976;48(4 Suppl):722–31.PubMed
179.
Hameed A, Beach FX, Kennedy RH, Barry RE. A case of clofazimine enteropathy. Int J Clin Pract. 1998;52(6):439–40.PubMed
180.
Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effects of multi-drug therapy in leprosy, a two years’ experience (2006–2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Lepr Rev. 2011;82(1):17–24.PubMed
181.
Parizhskaya M, Youssef NN, Di Lorenzo C, Goyal RK. Clofazimine enteropathy in a pediatric bone marrow transplant recipient. J Pediatr. 2001;138(4):574–6.PubMed
182.
Balakrishnan S, Desikan KV, Ramu G. Quantitative estimation of clofazimine in tissue. Lepr India. 1976;48(4 Suppl):732–8.PubMed
183.
184.
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153–61.PubMed
185.
Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of a standardized second line drugs treatment for chronic tuberculosis patients: national cohort study in Peru. Lancet. 2002;359:1980–9.PubMed
Metadata
Title
Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications
Authors
Geetha Ramachandran
Soumya Swaminathan
Publication date
01-03-2015
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2015
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-015-0267-y

Other articles of this Issue 3/2015

Drug Safety 3/2015 Go to the issue

Review Article

Neurodevelopmental Effects of Fetal Antiepileptic Drug Exposure

Leading Article

Drug Safety Meta-Analysis: Promises and Pitfalls

Original Research Article

Evaluation of an Automated Surveillance System Using Trigger Alerts to Prevent Adverse Drug Events in the Intensive Care Unit and General Ward

Review Article

Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis

Review Article

Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration

Current Opinion

Computational Approaches for Pharmacovigilance Signal Detection: Toward Integrated and Semantically-Enriched Frameworks